ARRY has been going down for too long since they they withdrawn their FDA application for its skin cancer drug binimetinib after poor P3 results.
Stock seems oversold atm. Yesterday's results were quite positive. May have a short squeeze.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
